Which medications should be avoided in a patient with end-stage renal disease (ESRD)?

Medications to Avoid in End-Stage Renal Disease

In patients with ESRD, avoid NSAIDs entirely, avoid meperidine/codeine/morphine due to toxic metabolite accumulation, avoid aminoglycosides unless absolutely necessary with close monitoring, and avoid tramadol/tapentadol completely. 1, 2

High-Priority Medications to Completely Avoid

NSAIDs (All Types)

• All NSAIDs must be avoided in ESRD (GFR <30 mL/min/1.73 m²) due to cardiovascular complications, fluid retention, and lack of renal prostaglandin-mediated blood flow regulation. 2, 3
• This includes both traditional NSAIDs (ibuprofen, naproxen, diclofenac, ketorolac) and COX-2 inhibitors (celecoxib). 2, 3, 4
• NSAIDs cause sodium retention averaging 5 mmHg blood pressure increase and can precipitate heart failure decompensation in dialysis patients. 3
• The combination of NSAIDs with ACE inhibitors/ARBs and diuretics creates a "perfect storm" dramatically increasing acute kidney injury risk, making this triple therapy absolutely contraindicated. 2, 3

Opioids with Toxic Metabolites

• Meperidine, codeine, and morphine are contraindicated in ESRD because their active metabolites (normeperidine, morphine-6-glucuronide, morphine-3-glucuronide) accumulate and cause neurotoxicity, respiratory depression, and seizures. 1, 2
• Tramadol and tapentadol are not recommended in ESRD due to accumulation and increased serotonergic toxicity risk. 1
• Hydrocodone, oxycodone, and hydromorphone require extreme caution with significant dose reduction if used at all. 1

Aminoglycoside Antibiotics

• Gentamicin, tobramycin, amikacin, kanamycin, streptomycin, and capreomycin should be avoided in ESRD due to irreversible ototoxicity and nephrotoxicity. 1, 2, 5, 6
• If aminoglycosides must be used, dose at 12-15 mg/kg two to three times per week (never daily), give immediately after hemodialysis, and monitor serum drug concentrations to avoid levels above 35 mcg/mL for amikacin or 12 mcg/mL for gentamicin. 1, 5, 6
• The risk of permanent bilateral deafness increases with cumulative exposure and cannot be predicted by symptoms during therapy. 5, 6

Medications Requiring Dose Adjustment (Not Avoidance)

Tuberculosis Medications

• Pyrazinamide and ethambutol require three-times-weekly dosing (not daily) in ESRD: pyrazinamide 25-35 mg/kg per dose, ethambutol 15-25 mg/kg per dose. 1
• Cycloserine requires either 250 mg once daily or 500 mg three times per week with careful neurotoxicity monitoring. 1
• Levofloxacin requires 750-1,000 mg per dose three times per week (not daily). 1
• Isoniazid and rifampin are metabolized hepatically and require no dose adjustment. 1
• All antituberculosis drugs should be administered immediately after hemodialysis to facilitate directly observed therapy and avoid premature drug removal. 1

Safe Opioid Alternatives in ESRD

• Fentanyl (transdermal or IV) is the safest opioid for ESRD because it undergoes hepatic metabolism without active metabolite accumulation. 1, 3
• Buprenorphine (transdermal) is the second-line safe option with metabolites 40 times less potent than the parent compound. 3
• Methadone is acceptable but requires administration only by experienced clinicians due to accumulation risk. 1

Preferred Analgesic Strategy in ESRD

First-Line Analgesic

• Acetaminophen up to 3 grams daily is the preferred first-line analgesic for all pain types in ESRD patients. 2, 3
• Acetaminophen provides pain relief comparable to NSAIDs without cardiovascular or fluid retention risks. 3

Second-Line Options

• Topical formulations (capsaicin cream, menthol) for localized pain without systemic absorption. 3
• Intra-articular glucocorticoids (triamcinolone) or hyaluronic acid for knee osteoarthritis. 3
• Short courses of oral corticosteroids for acute inflammatory flares. 3
• Carefully titrated fentanyl or buprenorphine for severe refractory pain. 3

Proton Pump Inhibitors (Use with Caution)

• Pantoprazole and other PPIs carry significant nephrotoxicity risk including acute interstitial nephritis and accelerated eGFR decline in ESRD. 7
• Discontinue PPIs if acute interstitial nephritis features appear (fever, rash, eosinophilia, sterile pyuria). 7
• Continue only when indication is compelling (active GI bleeding, severe erosive esophagitis, Zollinger-Ellison syndrome) and no alternative provides comparable efficacy. 7
• Monitor serum creatinine every 48 hours if PPIs must be continued during acute illness. 7

Critical Drug Combinations to Avoid

• Never combine NSAIDs with ACE inhibitors/ARBs plus diuretics (triple therapy) as this eliminates both prostaglandin-mediated vasodilation and angiotensin II-mediated pressure maintenance. 2, 3
• Avoid concurrent nephrotoxins: do not combine aminoglycosides with vancomycin, amphotericin B, cisplatin, contrast media, or other aminoglycosides. 1, 5, 6
• Avoid aminoglycosides with potent diuretics (furosemide, ethacrynic acid) as diuretics independently cause ototoxicity and enhance aminoglycoside tissue concentrations. 5, 6

Monitoring Requirements When High-Risk Drugs Cannot Be Avoided

• Measure serum drug concentrations for cycloserine, ethambutol, and all injectable agents to minimize dose-related toxicity. 1
• Obtain serial audiograms when using aminoglycosides in patients old enough to be tested. 5, 6
• Monitor for ototoxicity symptoms (dizziness, vertigo, tinnitus, roaring in ears, hearing loss) which mandate immediate drug discontinuation. 5, 6
• Check serum creatinine, BUN, and urine for decreased specific gravity, proteinuria, cells, or casts when using nephrotoxic agents. 5, 6

Common Pitfalls to Avoid

• Do not rely on serum creatinine alone to assess renal function in ESRD—it remains normal despite significantly reduced GFR, especially in elderly or low-muscle-mass patients. 2
• Do not extrapolate chronic kidney disease dosing guidelines to acute-on-chronic situations, as hepatic blood flow, protein binding, and CYP450 activity differ markedly. 7
• Do not assume peritoneal dialysis and hemodialysis have equivalent drug removal—drug clearance mechanisms differ substantially and require separate dosing strategies. 1
• Do not use over-the-counter medications or herbal remedies without nephrology consultation, as many have hidden nephrotoxic potential. 2
• Ensure coordination with the nephrology team for any medication changes in ESRD patients. 3